REC 0545, Recordati’s investigational treatment for maple syrup urine disease (MSUD), a rare genetic metabolic disorder that starts in early infancy, is among the latest products that the European Medicines Agency has begun reviewing for potential pan-EU marketing authorization.
MSUD, which gets its name from the distinctive sweet odor of urine in infants with the condition, is a disease in which the body is unable to properly process certain amino acids. The condition is characterized by lack of appetite, vomiting, lethargy, seizures, abnormal movements and developmental delay
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?